Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PEPD | P12955 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789984 | 1.00 | ACE (0.69) | ACELMNAHSD17B10CYP2C19KDM4E | |
| SCHEMBL6789982 | 1.00 | ACE (0.69) | ACELMNAHSD17B10CYP2C19KDM4E | |
| SCHEMBL7377396 | 0.95 | ACE (0.62) | ACELMNAHSD17B10CYP2C19KDM4E | |
| SCHEMBL3048970 | 0.90 | ACE (0.60) | ACELMNAHSD17B10CYP2C19KDM4E | |
| SCHEMBL7377569 | 0.89 | ACE (0.54) | ACELMNAHSD17B10CYP2C19KDM4E | |
| SCHEMBL6782705 | 0.89 | ACE (0.72) | ACEREN | |
| SCHEMBL6782701 | 0.89 | ACE (0.72) | ACEREN | |
| Miridesap SCHEMBL1685022 | 0.85 | ACE (0.68) | ACEREN | |
| SCHEMBL6794104 | 0.85 | ACE (0.68) | ACERENACE2 | |
| SCHEMBL6794095 | 0.85 | ACE (0.68) | ACERENACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0862556-B1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO INC (US) | 2001-09-05 | — | — | EP | claimed |
| EP-0862556-A4 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | claimed |
| WO-1998041211-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME | MERCK & CO., INC. (US) | 1998-09-24 | — | — | WO | claimed |
| EP-0862556-A1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | claimed |
| WO-1998025622-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| US-5763361-A | 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors | MERCK & CO., INC. (US) | 1998-06-09 | — | — | US | claimed |
| WO-1998009632-A1 | METHODS AND COMPOSITIONS FOR TREATING PRETERM LABOR | MERCK & CO., INC. (US) | 1998-03-12 | — | — | WO | claimed |
| WO-1997015558-A1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| US-20140032198-A1 | APPLICATION OF MULTIDIMENSIONAL MATRIX FOR DRUG MOLECULAS DESIGN AND THE METHODOLOGIES FOR DRUG MOLECULAR DESIGN | YAN JINGBO (CN) | 2014-01-30 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0862556-B1 | 17-ALKYL-7-SUBSTITUTED-4-AZA STEROID DERIVATIVES | MERCK & CO INC (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-0009898-B1 | NOVEL ANTI-HYPERTENSIVE MERCAPTOACYLAMINO ACID DERIVATIVES, THEIR PREPARATION AND USE | UNIVERSITY OF MIAMI (US) | 1983-05-18 | — | — | EP | disclosed |
| EP-0035383-A1 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-09 | — | — | EP | disclosed |
| EP-0009898-A1 | Novel anti-hypertensive mercaptoacylamino acid derivatives, their preparation and use | UNIVERSITY OF MIAMI (US) | 1980-04-16 | — | — | EP | disclosed |
| US-4154840-A | Antihypertensive pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4105776-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4046889-A | HYPOTENSIVE AGENTS, ENZYME INHIBITORS, ANGIOTENSIN CONVERSION | E. R. SQUIBB & SONS, INC. (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885LMNA 3688/4885HSD17B10 3423/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885LMNA 2155/4885HSD17B10 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.